Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydroge
Lost Money on Regeneron Pharmaceuticals, Inc. (REGN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
12:30pm, Friday, 06'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ
BENSALEM, Pa. , Dec. 6, 2024 /PRNewswire/ -- Law Offices of Howard G.
NEW YORK, NY / ACCESSWIRE / December 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ
Regeneron Pharmaceuticals, Inc. (REGN) Piper Sandler 36th Annual Healthcare Conference (Transcript)
02:55pm, Thursday, 05'th Dec 2024
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ) Piper Sandler 36th Annual Healthcare Conference Call December 5, 2024 9:30 AM ET Company Participants Ryan Crowe - Senior Vice President, Investor Relati
REGN ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Regeneron Pharmaceuticals, Inc. Shareholders Who Lost Money
01:15pm, Wednesday, 04'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ
LOS ANGELES, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Regeneron Pharmaceutica
BENSALEM, Pa., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ
Medigene Receives Milestone Payment from Regeneron Pharmaceuticals, Inc.
05:00am, Tuesday, 03'rd Dec 2024
Planegg/Martinsried, December 3, 2024. Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an oncology platform company focused on the research and development of T cell receptor (
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
12:00pm, Monday, 02'nd Dec 2024
LOS ANGELES , Dec. 2, 2024 /PRNewswire/ -- The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN) on behalf of i
NEW YORK, NY / ACCESSWIRE / November 29, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDA
LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Rege
NEW YORK, NY / ACCESSWIRE / November 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDA
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) investors
The Law Offices of Frank R. Cruz Continues Investigation of Regeneron Pharmaceuticals, Inc. (REGN) on Behalf of Investors
12:00pm, Monday, 25'th Nov 2024
LOS ANGELES, Nov. 25, 2024 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQ: REGN) on
